Skip to main content
Clinical Trials/NCT02728583
NCT02728583
Completed
Not Applicable

The Effects of a Low-fat Spread With Added Plant Sterol Esters and Fish Omega-3 Fatty Acids on Blood Lipids

Unilever R&D1 site in 1 country260 target enrollmentApril 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vascular Diseases
Sponsor
Unilever R&D
Enrollment
260
Locations
1
Primary Endpoint
Change in TG concentrations
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The main aim of the study is to investigate the effect of daily consumption of a margarine enriched with plant sterol esters and fish oil on fasting triglycerides (TG) concentrations.

The study also aims to investigate the effect of plant sterols and fish oil on fasting total cholesterol (TC), Low-density lipoprotein cholesterol (LDL-C), High-density lipoprotein cholesterol (HDL-C) and non-HDL-C.

At last, the effect of plant sterols and fish oil on fasting apolipoprotein concentrations will be explored.

Detailed Description

The main aim of the study is to investigate the effect of daily consumption of a margarine enriched with plant sterol esters and fish oil on fasting TG concentrations. The study also aims to investigate the effect of plant sterols and fish oil on fasting TC, LDL-C, HDL-C and non-HDL-C. At last, the effect of plant sterols and fish oil on fasting apolipoprotein concentrations will be explored. This exploratory objective will only be analyzed if a relevant treatment effect on fasting triglycerides concentrations is observed.

Registry
clinicaltrials.gov
Start Date
April 2016
End Date
January 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Unilever R&D
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Fasting TG levels at screening: ≥ 1.40 and ≤ 5.60 mmol/L
  • Fasting LDL-C levels at screening: ≥ 3.4 and ≤ 4.9 mmol/L

Exclusion Criteria

  • Recently (\<6 months) diagnosed with cardiovascular event(s), revascularization or systemic inflammatory conditions.
  • Medical history which might impact study measurements, to be judged by the study physician
  • Use of over-the-counter and prescribed medication which may interfere with study measurements
  • Reported weight loss or gain of 3 kg or more during a period of 2 months prior to screening.
  • Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months prior to screening and/or during the study.

Outcomes

Primary Outcomes

Change in TG concentrations

Time Frame: At baseline (after 2 weeks run-in period) and after 4 weeks intervention

Two samples will be taken at baseline (Day -1 and 1) and two samples at the end of intervention (Day 28 and 29)

Secondary Outcomes

  • Change in blood lipids(At baseline (after 2 weeks run-in period) and after 4 weeks intervention)

Study Sites (1)

Loading locations...

Similar Trials